Through the initiative, development of a screening program to test tumours for major genetic changes will occur.
In addition, it will aid in genetic testing of both patients and tumours enabling the use of specialised drugs that target specific genes and mutations that can cause or influence the development of cancer.
The project will initially look at mutations in breast, bowel, lung, prostate as well as ovarian cancer and melanoma.